Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's propranolol
hydrochloride extended-release 160 mg capsules to Wyeth's Inderal LA® 160 mg capsules
following a single, oral 160 mg (1 x 160 mg) dose administration under fasting conditions.